Cipla Unit Buys 100% Of Mabpharm, Maker Of Cancer Antibodies
This article was originally published in PharmAsia News
Executive Summary
Cipla's Meditab Specialties unit has bought the remaining shares it did not already own in another India-based drug maker, Mabpharm, and is making it a 100% subsidiary.